• Cemiplimab
    Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs...
    13 KB (1,060 words) - 00:29, 30 September 2024
  • Thumbnail for PD-1 and PD-L1 inhibitors
    PD-1 and PD-L1 inhibitors
    squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. Cemiplimab (Libtayo) was developed by Regeneron Pharmaceuticals and first approved...
    35 KB (3,450 words) - 03:38, 30 September 2024
  • Thumbnail for Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals
    $650 million from the development of REGN2810. REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best stock of...
    26 KB (2,290 words) - 23:04, 12 September 2024
  • Dostarlimab
    lymphoma, renal cell carcinoma, and breast cancer. Another PD-1 antibody is cemiplimab (Libtayo) which was approved for treatment of squamous cell carcinoma...
    37 KB (3,213 words) - 00:29, 30 September 2024
  • Thumbnail for Pembrolizumab
    Pembrolizumab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed...
    79 KB (7,368 words) - 00:29, 30 September 2024
  • Toripalimab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed...
    9 KB (603 words) - 00:28, 30 September 2024
  • Sanofi
    blood tests, lung and prostate cancer, marketed by Regeneron. Libtayo (Cemiplimab), for squamous cell skin cancer, marketed by Regeneron. Mozobil (Plerixafor)...
    92 KB (8,810 words) - 04:11, 13 September 2024
  • Thumbnail for Durvalumab
    Durvalumab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed...
    28 KB (2,721 words) - 04:14, 1 October 2024
  • Thumbnail for Nivolumab
    Nivolumab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed...
    47 KB (4,870 words) - 00:30, 30 September 2024
  • Retifanlimab
    inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed...
    9 KB (460 words) - 00:28, 30 September 2024